

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\075\2024-25
Date: 24.01.2025

B S E Limited,
P J Towers, Dalal Street,
Mumbai: 400001.
Scrip Code No.524394

National Stock Exchange of India Limited,
"Exchange Plaza", Bandra,
Kurla Complex, Bandra (E),
Mumbai – 400051.
Trading Symbol: VIMTALABS

Dear Sir/Madam,

Sub – Press Release – Unaudited Financial Results – 31st December, 2024.
Ref- Regulation 30 of SEBI (Listing obligations and disclosure requirements) Regulations, 2015.

With reference to the subject cited above, please find attached the press release in connection with the announcement of unaudited Standalone and Consolidated Financial Results for the 3rd quarter and nine months ended 31st December, 2024.

This is for your information and records.

Thanking you,

For VIMTA LABS LIMITED

Sujani Vasireddi
Company Secretary



Attachments: as above.

Vimta Labs Limited Reports Q3 & 9M FY25 Results

**Q3 FY25 Total Income at Rs. 911 Mn,
EBITDA margins at 37.6%; PAT margin at 19.2%**

Hyderabad, January 24, 2025: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter and nine months ended December 31, 2024.

Consolidated Financial Results – Q3 & 9M FY25:

Particulars (Rs. Mn)	Q3 FY25	Q3 FY24	YoY (%)	Q2 FY25	QoQ(%)	9M FY25	9M FY24	YoY (%)
Total Income	911	753	21.1%	854	6.7%	2521	2192	15.0%
EBITDA (including other income)	343	246	39.4%	306	12.2%	915	715	28.1%
EBITDA Margin	37.6%	32.7%	496 bps	35.8%	184 bps	36.3%	32.6%	370 bps
PAT (continued operations)	175	123	43.0%	170	2.9%	484	349	39.0%
PAT Margin	19.2%	16.3%	294 bps	19.9%	70 bps	19.2%	15.9%	331 bps
Basic EPS	7.9	5.5	42.4%	7.7	2.1%	21.8	15.7	38.9%

Note: Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period

Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said: "We are happy to report that Vimta Labs had another successful quarter with a strong growth of 21.1% YoY. This was mainly pushed by the Drug Development & Discovery Services. EBITDA margin for the quarter stood at 37.6% which is a growth of 496 bps on a YoY basis.

During the quarter, our new addition to the Life Sciences Facility, was commercialised which has helped ease our operations giving us the space to work more efficiently.

As we look to the future, we remain optimistic about our strategic direction and the robustness of our service offerings, which we believe will drive sustained growth and success."

Q3 FY25 Business Updates:

- 11th October 2024, Business Transfer of CRM to Thyrocare.
- Relocated Pune food testing lab to Nashik with a view to be closer to agri produce regions.
- New addition to Life Sciences Facility was commercialised partially in this quarter.
- A successful cGMP regulatory audit outcome from inspection conducted by Turkey Drug regulator.
- EMTAC merger with Vimta: Scheme has been sanctioned by NCLT Hyderabad bench.

Key Result Highlights for the Q3 & 9M FY25 (Consolidated):

Q3 FY25

- ✓ Total Income for Q3 FY25 was at Rs. 911 Mn
- ✓ EBITDA for Q3 FY25 was Rs. 343 Mn; EBITDA margin was at 37.6%
- ✓ PBT for Q3 FY25 was at Rs. 239 Mn
- ✓ Q3 FY25 PAT* was at Rs. 175 Mn; PAT margin was at 19.2%
- ✓ Basic EPS in Q3 FY25 was Rs. 7.9

9M FY25

- ✓ Total Income for 9M FY25 was at Rs. 2,521 Mn
- ✓ EBITDA for 9M FY25 was Rs. 915 Mn; EBITDA margin was at 36.3%
- ✓ PBT for 9M FY25 was at Rs. 640 Mn
- ✓ 9M FY25 PAT* was at Rs. 484 Mn; PAT margin was at 19.2%
- ✓ Basic EPS in 9M FY25 was Rs. 21.8
- ✓ Total Debt as of 31st December 2024 stood at Rs. 113 Mn
- ✓ Cash and Cash equivalents including bank balance stood at Rs. 180 Mn as of 31st December 2024

Note:

* Profit/(Loss) for the period from continuing operations

^ Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period

ABOUT VIMTA LABS LIMITED:

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services.

CAUTIONARY STATEMENT:

This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

PRESS RELEASE

For Immediate dissemination



For details, please contact:

<p>Investor Relations at Vimta Labs mdoffice@vimta.com Ernst & Young Mr. Siddesh Chawan Siddesh.Chawan@in.ey.com Mr. Advait Bhadekar Advait.bhadekar@in.ey.com</p>	<p>Registered Office Plot Number 142, IDA Phase 2, Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: www.vimta.com</p>
---	--